Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Other Accumulated Expenses (2016 - 2025)

Iradimed (IRMD) has disclosed Other Accumulated Expenses for 13 consecutive years, with $296207.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 18.48% to $296207.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $296207.0, a 18.48% increase, with the full-year FY2024 number at $162998.0, down 34.8% from a year prior.
  • Other Accumulated Expenses was $296207.0 for Q3 2025 at Iradimed, down from $324644.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $324644.0 in Q2 2025 to a low of $121919.0 in Q4 2022.
  • A 5-year average of $211011.9 and a median of $250000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 71.18% in 2021, then soared 105.05% in 2023.
  • Iradimed's Other Accumulated Expenses stood at $146435.0 in 2021, then dropped by 16.74% to $121919.0 in 2022, then soared by 105.05% to $250000.0 in 2023, then crashed by 34.8% to $162998.0 in 2024, then soared by 81.72% to $296207.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Other Accumulated Expenses are $296207.0 (Q3 2025), $324644.0 (Q2 2025), and $256980.0 (Q1 2025).